Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer [0.03%]
培美曲塞维持治疗晚期非鳞状非小细胞肺癌
Seigo Minami,Takashi Kijima
Seigo Minami
Pemetrexed, a multitargeting antifolate cytotoxic drug, plays a leading role in front-line chemotherapy for patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Following its approval as second-line monotherapy for locall...
Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy [0.03%]
超微创精准瘤内化疗免疫治疗晚期肺癌的半抗原增强效应
Baofa Yu,Yuanfei Lu,Feng Gao et al.
Baofa Yu et al.
Aim: The objective of the study reported here was to evaluate the therapeutic effects of hapten-enhanced chemoimmunotherapy in the treatment of advanced lung cancer by ultra-minimum incision personalized intratumoral chem...
Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics [0.03%]
表皮生长因子受体突变型非小细胞肺癌的靶向治疗：关注吉非替尼伴随诊断的使用
Niki Karachaliou,Rafael Rosell
Niki Karachaliou
Deeper understanding of the pathobiology of non-small-cell lung cancer (NSCLC) has led to the development of small molecules that target genetic mutations known to play critical roles in the progression to metastatic disease. The discovery ...
Terunaga Inage,Takahiro Nakajima,Ichiro Yoshino
Terunaga Inage
Accurate staging is the first step in the management of lung cancer. Nodal staging is quite important for physicians to be able to judge the primary operability of patients harboring no distant metastasis. For many years, mediastinoscopy ha...
Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB-IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities [0.03%]
立体定向体部放射治疗老年ⅡB～Ⅳ期非小细胞肺癌患者的研究（不适合或拒绝其他治疗模式的患者）
Sana D Karam,Zachary D Horne,Robert L Hong et al.
Sana D Karam et al.
Objective: In elderly patients with stage IIB-IV nonsmall cell lung cancer who cannot tolerate chemotherapy, conventionally fractionated radiotherapy is the treatment of choice. We present our experience with hypofraction...
Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence [0.03%]
尼达尼布治疗晚期非小细胞肺癌二线治疗的临床潜力：现有证据
Sacha I Rothschild
Sacha I Rothschild
The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing. The description of molecular alterations leading to NSCLC carcinogenesis and progression (so-called oncogenic driver mutations) and the development of targeted age...
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer [0.03%]
巴维妥昔单抗的临床前和临床概况及其在非小细胞肺癌治疗中的潜力
Irene Stasi,Federico Cappuzzo
Irene Stasi
Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a specific mechanism of action. PS is an anionic membrane phospholipid...
New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer [0.03%]
难治性ALK阳性转移性非小细胞肺癌治疗的新选择
Amy M Weise,Shirish Gadgeel
Amy M Weise
Non-small-cell lung cancer (NSCLC) is a heterogeneous disease and a challenging malignancy to treat, as many patients have advanced disease at the time of diagnosis. Recent advances have led to the identification of molecularly defined subt...
The voice of postsurgical lung cancer patients regarding supportive care needs [0.03%]
有关肺癌术后患者支持性护理需求的声音
Amy J Hoffman,Ruth Ann Brintnall,Alexander von Eye et al.
Amy J Hoffman et al.
Objective: Individuals with lung cancer present with multiple comorbid conditions and complex treatment plans. They are frequently vulnerable during critical transitions in the cancer survivorship trajectory. Limited rese...
Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair [0.03%]
胃食管结合部腺癌同源重组及核苷酸切除修复异常
Robin I Dewalt,Kenneth A Kesler,Zane T Hammoud et al.
Robin I Dewalt et al.
Objective: Esophageal adenocarcinoma (EAC) continues to be a disease associated with high mortality. Among the factors leading to poor outcomes are innate resistance to currently available therapies, advanced stage at dia...